Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ajanta PharmaNSE:AJANTPHARM -0.66%95 PB Ratio is 9.61 as of Sep. 03, 2026, which is 70% above its 10-year median of 5.65. GuruFocus rates NSE:AJANTPHARM with a GF Score™ of 95/100 and a GF Value™ of ₹3,348.50 (Fairly Valued). The stock has 6 warning signs investors should review. Among 917 Drug Manufacturers companies, Ajanta Pharma ranks worse than 91.82% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-09-03), Ajanta Pharma's share price is ₹3481.70. Ajanta Pharma's Book Value per Share for the quarter that ended in Jun. 2026 was ₹362.35. Hence, Ajanta Pharma's PB Ratio of today is 9.61.
Warning Sign:
Ajanta Pharma Ltd stock PB Ratio (=9.82) is close to 1-year high of 9.82.
The historical rank and industry rank for Ajanta Pharma's PB Ratio or its related term are showing as below:
NSE:AJANTPHARM'
s PB Ratio Range Over the Past 10 Years
Min: 3.37 Med: 5.65 Max: 12.46
Current: 9.56
During the past 13 years, Ajanta Pharma's highest PB Ratio was 12.46. The lowest was 3.37. And the median was 5.65.
NSE:AJANTPHARM's PB Ratio is ranked worse than 91.82% of 917
companies
in the Drug Manufacturers industry
Industry Median: 1.98
vs NSE:AJANTPHARM: 9.56
During the past 12 months, Ajanta Pharma's average Book Value Per Share Growth Rate was 19.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 10.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 8.40% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 13.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Ajanta Pharma was 44.70% per year. The lowest was 6.00% per year. And the median was 18.70% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Ajanta Pharma PB Ratio Related Terms
Ajanta Pharma PB Ratio Historical Data
* Premium members only.
The historical data trend for Ajanta Pharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ajanta Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ajanta Pharma PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ajanta Pharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where Ajanta Pharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Ajanta Pharma's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Ajanta Pharma (NSE:AJANTPHARM) has a PB Ratio of 9.61 as of Sep. 03, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Ajanta Pharma and its competitors. This is 70% above median its historical median of 5.65. Over the past decade, Ajanta Pharma's PB Ratio has ranged from 3.37 to 12.46. According to the industry distribution chart, Ajanta Pharma ranks #842 out of 917 companies in the Drug Manufacturers industry, placing it in the top 91.8%.
Is Ajanta Pharma's PB Ratio too high?
Ajanta Pharma's current PB Ratio of 9.61 is 70% above median its 10-year median of 5.65. Over the past 10 years, this metric has ranged from a low of 3.37 to a high of 12.46. The Drug Manufacturers industry median PB Ratio is 1.98. Ajanta Pharma's value of 9.61 is 385.4% above this industry median. Based on the distribution chart, Ajanta Pharma ranks #842 out of 917 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Ajanta Pharma has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ajanta Pharma's PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Ajanta Pharma ranks #842 out of 917 companies for PB Ratio. This places Ajanta Pharma in the lower half of its industry. The industry median PB Ratio is 1.98. Ajanta Pharma's value of 9.61 is 385.4% above this benchmark. Historically, Ajanta Pharma's own PB Ratio has ranged from 3.37 to 12.46 over the past decade. While the company's 10-year median is 5.65 vs. the industry median of 1.98, Ajanta Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.98, based on 917 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ajanta Pharma's current PB Ratio of 9.61 is 385.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Ajanta Pharma and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ajanta Pharma's current PB Ratio is 9.61, which is 70% above median its own 10-year median of 5.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ajanta Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ajanta Pharma (NSE:AJANTPHARM) is currently considered Fairly Valued. The stock's GF Value™ is ₹3,348.50, compared to a current price of ₹3,481.70 — trading 4% above its estimated fair value. The current PB Ratio is 9.61, which is 70% above median its 10-year median of 5.65 and 385.4% above the Drug Manufacturers industry median of 1.98. Ajanta Pharma's overall GF Score™ is 95/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Ajanta Pharma (NSE:AJANTPHARM), the current PB Ratio is 9.61 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ajanta Pharma (NSE:AJANTPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Ajanta Pharma stock appears to be overvalued.
The current stock price of ₹3,481.70 is trading 4% above its estimated GF Value™ of ₹3,348.50.
GuruFocus considers Ajanta Pharma to be Fairly Valued.
Key valuation signals for NSE:AJANTPHARM:
PB Ratio: 9.61 (70% above median its 10-year median of 5.65)
GF Value™: ₹3,348.50 vs. price of ₹3,481.70 (4% above fair value)
Industry Position: 385.4% above the Drug Manufacturers median (#842 of 917)
No single metric tells the full story. See the NSE:AJANTPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ajanta Pharma Ltd is mainly involved in development, manufacturing and marketing of speciality pharmaceutical finished dosages. The operations of the Group are limited to only one segment viz. pharmaceuticals and related products. The company has presence in India, Emerging Market, Africa Institution, and USA. The company generates majority of revenue from Emerging market.
95GF Score
Get the complete analysis for NSE:AJANTPHARM
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AJANTPHARM has been successfully added to your 
